Showing results (311-320 of 415) with videos related to
Sort By:
Pageof 42
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001
Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23B Fisher, S Anderson, E Tan-Chiu, et al.Blood Advances|September 2, 2022
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Elizabeth Bengston, Robert Redd, et al.Leukemia & Lymphoma|December 3, 2011
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplantAndrew A Lane, Philippe Armand, Yang Feng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22B Fisher, S Anderson, D L Wickerham, et al.International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
5-5-5 ABRT (Dose of 5 Gy per Fraction for up to 5 Fractions Over 5 Weeks Adaptive Bridging Radiation Therapy)-Artificial Intelligence Enters the CAR (-T) (Chimeric Antigen Receptor-T) in Relapsed/Refractory Large B Cell LymphomaHazim S Ababneh, Andrea K Ng, Joshua Wan, et al.Osteoarthritis and Cartilage|February 19, 2008
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelinesW Zhang, R W Moskowitz, G Nuki, et al.Osteoarthritis and Cartilage|August 28, 2007
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidenceW Zhang, R W Moskowitz, G Nuki, et al.British Journal of Haematology|November 14, 2013
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphomaMichelle Fanale, Sarit Assouline, John Kuruvilla, et al.Blood Advances|September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCLJeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.Pain|March 11, 2016
A randomized controlled trial of gabapentin for chronic low back pain with and without a radiating componentJ Hampton Atkinson, Mark A Slater, Edmund V Capparelli, et al.Pageof 42